SG11201901438VA - Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate - Google Patents
Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylateInfo
- Publication number
- SG11201901438VA SG11201901438VA SG11201901438VA SG11201901438VA SG11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA SG 11201901438V A SG11201901438V A SG 11201901438VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- solid forms
- cenicriviroc mesylate
- pct
- cambridge
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382153P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/049400 WO2018045043A1 (en) | 2016-08-31 | 2017-08-30 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901438VA true SG11201901438VA (en) | 2019-03-28 |
Family
ID=61241572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901438VA SG11201901438VA (en) | 2016-08-31 | 2017-08-30 | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10301287B2 (enExample) |
| EP (1) | EP3506896A4 (enExample) |
| JP (2) | JP2019526628A (enExample) |
| KR (1) | KR20190057066A (enExample) |
| CN (1) | CN110167550A (enExample) |
| AU (1) | AU2017321594A1 (enExample) |
| BR (1) | BR112019003987A2 (enExample) |
| CA (1) | CA3034606A1 (enExample) |
| MX (1) | MX2019002057A (enExample) |
| RU (1) | RU2019109019A (enExample) |
| SG (1) | SG11201901438VA (enExample) |
| TW (1) | TW201823235A (enExample) |
| WO (1) | WO2018045043A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019238041A1 (zh) * | 2018-06-12 | 2019-12-19 | 南京明德新药研发有限公司 | 一种丙烯酰胺类化合物的晶型及其制备方法 |
| WO2019245518A1 (en) * | 2018-06-18 | 2019-12-26 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US20210379824A1 (en) * | 2018-06-18 | 2021-12-09 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11298876B2 (en) | 2018-06-19 | 2022-04-12 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11426931B2 (en) | 2018-06-19 | 2022-08-30 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| US11591486B2 (en) | 2018-06-19 | 2023-02-28 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| CN112638995B (zh) * | 2018-08-31 | 2024-03-19 | 赢创运营有限公司 | 制备聚合物粉末的方法 |
| WO2021133811A1 (en) | 2019-12-26 | 2021-07-01 | Teva Pharmaceuticals International Gmbh | Solid state forms of cenicriviroc and process for preparation thereof |
| CA3179593A1 (en) | 2020-05-22 | 2021-11-25 | Yunfu Luo | Pyridine derivative and application thereof |
| EP4296077B1 (en) * | 2021-02-22 | 2025-05-14 | Asahi Kasei Kabushiki Kaisha | Composition containing cellulose nanofibers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62265270A (ja) | 1986-05-13 | 1987-11-18 | Zeria Shinyaku Kogyo Kk | 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤 |
| ATE199721T1 (de) | 1994-07-04 | 2001-03-15 | Takeda Chemical Industries Ltd | Phosphonsäure verbindungen imre herstellung und verwendung |
| CN1282243A (zh) | 1997-12-19 | 2001-01-31 | 武田药品工业株式会社 | 用于拮抗ccr5的含n－酰苯胺衍生物的药物组合物 |
| CA2337307A1 (en) | 1998-08-20 | 2000-03-02 | Osamu Nishimura | Quaternary ammonium salts and their use |
| WO2001017947A1 (en) | 1999-09-06 | 2001-03-15 | Takeda Chemical Industries, Ltd. | Process for the preparation of 2,3-dihydroazepine compounds |
| ATE539062T1 (de) | 2001-08-08 | 2012-01-15 | Tobira Therapeutics Inc | Bizyklishe verbindung, ihre herstellung und verwendung |
| JP2004123694A (ja) * | 2002-03-12 | 2004-04-22 | Takeda Chem Ind Ltd | 光学活性スルホキシド誘導体の製造法 |
| WO2005089714A1 (ja) | 2004-03-24 | 2005-09-29 | Takeda Pharmaceutical Company Limited | エマルション安定化製剤 |
| JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
| GT200600148A (es) | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2012068366A2 (en) | 2010-11-18 | 2012-05-24 | Yale University | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus |
| AU2013257951A1 (en) * | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
| MX383706B (es) | 2013-05-15 | 2025-03-14 | Tobira Therapeutics Inc | Composiciones de cenicriviroc y métodos para elaborarlas y usarlas. |
| BR112016021682A2 (pt) * | 2014-03-21 | 2018-06-26 | Tobira Therapeutics, Inc. | cenicriviroc para o tratamento da fibrose |
| US20170105969A1 (en) * | 2014-06-02 | 2017-04-20 | Tobira Therapeutics, Inc. | Cenicriviroc for the treatment of hiv-2 infection |
| US10526349B2 (en) | 2014-12-23 | 2020-01-07 | Tobira Therapeutics, Inc. | Process of making cenicriviroc and related analogs |
-
2017
- 2017-08-30 JP JP2019531594A patent/JP2019526628A/ja active Pending
- 2017-08-30 MX MX2019002057A patent/MX2019002057A/es unknown
- 2017-08-30 SG SG11201901438VA patent/SG11201901438VA/en unknown
- 2017-08-30 RU RU2019109019A patent/RU2019109019A/ru not_active Application Discontinuation
- 2017-08-30 TW TW106129555A patent/TW201823235A/zh unknown
- 2017-08-30 WO PCT/US2017/049400 patent/WO2018045043A1/en not_active Ceased
- 2017-08-30 CA CA3034606A patent/CA3034606A1/en not_active Abandoned
- 2017-08-30 BR BR112019003987A patent/BR112019003987A2/pt not_active Application Discontinuation
- 2017-08-30 US US15/691,191 patent/US10301287B2/en active Active
- 2017-08-30 CN CN201780061529.6A patent/CN110167550A/zh active Pending
- 2017-08-30 KR KR1020197008786A patent/KR20190057066A/ko not_active Withdrawn
- 2017-08-30 EP EP17847477.1A patent/EP3506896A4/en not_active Withdrawn
- 2017-08-30 AU AU2017321594A patent/AU2017321594A1/en not_active Abandoned
-
2022
- 2022-07-14 JP JP2022113230A patent/JP2022137223A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3034606A1 (en) | 2018-03-08 |
| US20180057481A1 (en) | 2018-03-01 |
| JP2022137223A (ja) | 2022-09-21 |
| RU2019109019A3 (enExample) | 2021-08-23 |
| TW201823235A (zh) | 2018-07-01 |
| RU2019109019A (ru) | 2020-10-01 |
| JP2019526628A (ja) | 2019-09-19 |
| WO2018045043A1 (en) | 2018-03-08 |
| EP3506896A4 (en) | 2020-08-26 |
| US10301287B2 (en) | 2019-05-28 |
| BR112019003987A2 (pt) | 2019-05-28 |
| EP3506896A1 (en) | 2019-07-10 |
| AU2017321594A1 (en) | 2019-04-18 |
| MX2019002057A (es) | 2019-11-18 |
| KR20190057066A (ko) | 2019-05-27 |
| CN110167550A (zh) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201909495PA (en) | Combination cancer immunotherapy with pentaaza macrocyclic ring complex | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201806623VA (en) | Bacteria over-expressing c-di-amp and therapeutic methods | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |